Welcome to the international HTA database

Showing [23806 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2023	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Health technology assessment framework: adaptation for digital health technology assessment]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: assessment of the relevance of tandem mass spectrometry-based newborn blood spot screening for very long-chain acyl-CoA dehydrogenase deficiency (VLCADD)]
2023	NIHR Health and Social Care Delivery Program	Rapid evaluation of service innovations in health and social care: key considerations
2023	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Update: Functioning and disability - An evidence map]
2023	NIHR Health Services and Delivery Research programme	A rapid mixed-methods evaluation of remote home monitoring models during the COVID-19 pandemic in England
2023	NIHR Health Services and Delivery Research programme	What happens after an NHS Health Check? A survey and realist review
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Non-invasive monitoring of intracranial compliance and intracranial pressure in central nervous system lesions]
2023	NIHR Health Services and Delivery Research programme	Identifying models of care to improve outcomes for older people with urgent care needs: a mixed methods approach to develop a system dynamics model
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Angioplasty and stenting in patients with carotid artery stenosis]
2023	Austrian Institute for Health Technology Assessment (AIHTA)	Biomarkers in Alzheimer's disease
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Lecanemab in Alzheimer’s Disease]
2023	NIHR Health Services and Delivery Research programme	Explanation of context, mechanisms and outcomes in adult community mental health crisis care: the MH-CREST realist evidence synthesis
2023	Belgian Health Care Knowledge Centre (KCE)	Silicone adhesive multilayer foam dressings to prevent hospital-acquired pressure ulcers: a Belgian RCT-based economic evaluation
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Mobile cardiopulmonary exercise test in athletes or cardiopulmonary rehabilitation]
2023	NIHR Health Services and Delivery Research programme	Integration, effectiveness and costs of different models of primary health care provision for people who are homeless: an evaluation study
2023	Norwegian Institute of Public Health (NIPH)	Treatments for relapsing and/or refractory multiple myeloma. A health technology assessment
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Lipogems® System for autologous adipose tissue-derived mesenchymal stem cells transfer in orthopedic conditions]
2023	NIHR Health Services and Delivery Research programme	Vertical integration of general practices with acute hospitals in England: rapid impact evaluation
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: use of platelet-rich plasma for the treatment of knee osteoarthritis]
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Holmium laser in non-prostate endourologic conditions]
2023	NIHR Health Technology Assessment programme	Frenotomy with breastfeeding support versus breastfeeding support alone for infants with tongue-tie and breastfeeding difficulties: the FROSTTIE RCT
2023	NIHR Health Technology Assessment programme	Integration, effectiveness and costs of different models of primary health care provision for people who are homeless: an evaluation study
2023	NIHR Health Technology Assessment programme	Motivational support intervention to reduce smoking and increase physical activity in smokers not ready to quit: the TARS RCT
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Sapropterin in patients with phenylketonuria]
2023	NIHR Health Technology Assessment programme	A randomised controlled trial of adjunctive triamcinolone acetonide in eyes undergoing vitreoretinal surgery for open globe trauma – the ASCOT study
2023	NIHR Health Technology Assessment programme	Total ankle replacement versus ankle arthrodesis for patients aged 50–85 years with end-stage ankle osteoarthritis: the TARVA RCT
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Combination diagnostic tests offered as part of preventive health checks exams in overall population]
2023	NIHR Health Technology Assessment programme	Helping pregnant smokers quit: a multi-centre randomised controlled trial of electronic cigarettes versus nicotine replacement therapy
2023	Haute Autorite de sante (HAS)	[Comparative genomic hybridization array (CGHA) analysis in postnatal context]
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Polymeric diet rich in TGF-β for inflammatory bowel disease in pediatric patients]
2023	NIHR Health Technology Assessment programme	Cost-effectiveness of therapeutics for COVID-19 patients: a rapid review and economic analysis
2023	National Authority for Assessment and Accreditation in Healthcare (INEAS)	[Kadcyla® (trastuzumab emtansine) in the treatment of HER2-positive breast cancer : A rapid review]
2023	NIHR Public Health Research (PHR) programme	A multicomponent psychosocial intervention to reduce substance use by adolescents involved in the criminal justice system: the RISKIT-CJS RCT
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Triple-phase computed tomography in patients with liver lesion]
2023	NIHR Health Technology Assessment programme	Antidepressants in pregnancy: applying causal epidemiological methods to understand service-use outcomes in women and long-term neurodevelopmental outcomes in exposed children
2023	National Authority for Assessment and Accreditation in Healthcare (INEAS)	[Autologous adipose-derived stem cells for chronic wounds treatment : Full HTA report]
2023	NIHR Public Health Research (PHR) programme	Impact of a social prescribing intervention in North East England on adults with type 2 diabetes: the SPRING_NE multimethod study
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Dielectric radiofrequency for the treatment of primary hyperhidrosis and bromhidrosis]
2023	NIHR Health Technology Assessment programme	Insights from UKCTOCS for design, conduct and analyses of large randomised controlled trials
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Transbronchial biopsy guided by endobronchial ultrasound (EBUS) in pathologies accesible by transbronchial puncture that required anatomopathological diagnosis]
2023	NIHR Health Services and Delivery Research programme	Understanding what affects psychological morbidity in informal carers when providing care at home for patients at the end of life: a systematic qualitative evidence synthesis
2023	The Danish Health Technology Council (DHTC)	[Assessment concerning glucose monitoring for the treatment of adult patients with type 1 diabetes]
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Invasive electroencephalography for drug-resistant epilepsy]
2023	NIHR Health Technology Assessment programme	Extracorporeal carbon dioxide removal compared to ventilation alone in patients with acute hypoxaemic respiratory failure: cost-utility analysis of the REST RCT
2023	Norwegian Institute of Public Health (NIPH)	[Brace compression for treatment of pectus carinatum: a rapid health technology assessment]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guides and standards: the management of myalgic encephalomyelitis / chronic fatigue syndrome]
2023	Austrian Institute for Health Technology Assessment (AIHTA)	Robot-assisted surgery in thoracic and visceral indications – Update 2023
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Concept for routine practice data collection – Valoctocogen roxaparvovec: review of the study protocol (version 2.0) and the statistical analysis plan (version 2.0) – 3. Addendum to project A22-20]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guides and standards: Syphilis - detection, diagnosis, optimal antibiotic use, and follow-up]
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Fenfluramine (Dravet syndrome, ≥ 2 years)]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: benchmarks to improve services for at-risk or neglected children and their families]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: organizational models for the management of spinal cord injuries]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: resuscitation in community opioid overdose ‒ update and complement to INESSS guidance published in 2018 - Cardiopulmonary resuscitation (CPR) in a context of community-based naloxone administration for opioid overdose]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Fidanacogene elaparvovec (haemophilia B); assessment according to §35a Social Code Book (SGB) V; search for disease registries]
2023	Ontario Health	Robotic-assisted partial nephrectomy for kidney cancer
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivosidenib (acute myeloid leukaemia, IDH1 R132 mutation, first line, combination with azacitidine) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023	Ontario Health	Robotic-assisted hysterectomy for endometrial cancer in people with obesity
2023	Norwegian Institute of Public Health (NIPH)	[Triclosan coated sutures for prevention of surgical site infection: a health technology assessment]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivosidenib (cholangiocarcinoma) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023	Ontario Health	Carrier screening programs for cystic fibrosis, fragile X syndrome, hemoglobinopathies and thalassemia, and spinal muscular atrophy
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Mirikizumab (ulcerative colitis) - Benefit assessment according to § 35a Social Code Book V]
2023	NIHR Health Technology Assessment programme	Tonsillectomy compared with conservative management in patients over 16 years with recurrent sore throat: the NATTINA RCT and economic evaluation
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lumacaftor/ivacaftor (cystic fibrosis, 1 to < 2 years, F508del mutation, homozygous) – Benefit assessment according to §35a Social Code Book V]
2023	NIHR Health Technology Assessment programme	A multifaceted intervention to reduce antibiotic prescribing among CHIldren with acute COugh and respiratory tract infection: the CHICO cluster RCT
2023	Scottish Health Technologies Group (SHTG)	Tumour profiling tests to guide chemotherapy decisions in early breast cancer
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dimethyl fumarate (relapsing remitting multiple sclerosis) –Benefit assessment according to §35a Social Code Book V]
2023	Scottish Health Technologies Group (SHTG)	Community based respiratory care services for patients with chronic respiratory conditions
2023	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Electromagnetic Navigation Bronchoscopy: Use in Dying for Lung Nodules Resection. Horizon Scanning Technologies]
2023	Scottish Health Technologies Group (SHTG)	Outpatient biopsies (re-usable and disposable) equipment for suspicious laryngeal and pharyngeal lesions
2023	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Robotic Bronchoscopy for Lung Nodule Diagnostics. Horizon Scanning Technologies]
2023	Scottish Health Technologies Group (SHTG)	The clinical effectiveness and cost effectiveness of a digital type 2 diabetes remission programme
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Evaluation of invitation letters and information for insured persons on colorectal cancer screening]
2023	Andalusian Health Technology Assessment Area (AETSA)	[Clinical effectiveness and safety of newborn screening for spinal muscular atrophy. Systematic review]
2023	Scottish Health Technologies Group (SHTG)	The cost-effectiveness of the Scottish Hip Fracture Audit
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tremelimumab and durvalumab (NSCLC) – Second addendum to Project A23-29 \| A23-31]
2023	The Danish Health Technology Council (DHTC)	[Use of artificial intelligence as clinical decision-support in colonoscopy for the diagnosis of neoplastic disease]
2023	Scottish Health Technologies Group (SHTG)	Outpatient parenteral antimicrobial therapy (OPAT) cost calculator
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Selumetinib (neurofibromatosis) - Assessment according to §35a (para 1., sentence 11) Social Code Book V (expiry of the decision)]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tremelimumab and durvalumab (NSCLC) - Addendum to Commissions A23-29 and A23-31]
2023	Center for Drug Evaluation (CDE)	[Latest trend in consumption and utilization of schedule I and II controlled drugs - a nationwide population-based data in Taiwan
2023	NIHR Health Technology Assessment programme	One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT
2023	Scottish Health Technologies Group (SHTG)	Placental growth factor (PlGF)-based testing to help diagnose suspected preterm pre-eclampsia
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Durvalumab (malignant biliary tract cancer [BTC]) – Addendum to Commission A23-26]
2023	Haute Autorite de sante (HAS)	[Assessment of the exhaled nitric oxide measurement for asthma management]
2023	National Institute for Health and Care Excellence (NICE)	AposHealth for knee osteoarthritis. NICE medical technologies guidance 76
2023	Health Information and Quality Authority (HIQA)	Health technology assessment of the addition of severe combined immunodeficiency (SCID) to the National Newborn Bloodspot Screening Programme
2023	Scottish Health Technologies Group (SHTG)	An assessment of the Feeling Good app
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dupilumab (prurigo nodularis) – Addendum to Project A23-24]
2023	Scottish Health Technologies Group (SHTG)	Consideration of selective internal radiation therapies (SIRT) for treating primary hepatocellular carcinoma (liver cancer)
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Darolutamide (prostate cancer) - Addendum to Commission A23-21]
2023	Scottish Health Technologies Group (SHTG)	Store-and-forward teledermatology for triage of primary care referrals
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Esketamine (treatment-resistant major depressive disorder) – Addendum to Commission A23-18]
2023	Scottish Health Technologies Group (SHTG)	Orthotic bracing for the treatment of idiopathic scoliosis in children and young people (less than 18 years)
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Luspatercept (non-transfusion-dependent beta-thalassaemia) - Addendum to Commission A23-20]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Axicabtagene ciloleucel (diffuse large B-cell lymphoma, second line) – Benefit assessment according to §35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Axicabtagene ciloleucel (DLBCL and PMBCL, third line) – Benefit assessment according to §35a Social Code Book V]
2023	Swiss Federal Office of Public Health (FOPH)	Oral anticoagulants for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation
2023	Haute Autorite de sante (HAS)	[Assessment of the Endotest® saliva test in complex endometriosis diagnosis situations]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Transcutaneous vagus nerve stimulation in pharmacoresistant epilepsy –Third addendum to Commission E16-03]
2023	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Evaluation of taking mifepristone at home during a medical abortion]